ReviewTrends in biochemical sciences2026
Magical moments in protease biology: proteasome autocatalytic activation and PI31-mediated inhibition.
Review in Trends in biochemical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proteases regulate nearly every aspect of cellular function. Spatial and temporal control of protease activity contributes to this functional versatility and includes both zymogen activation mechanisms and the existence of dedicated protease inhibitors. Unlike conventional proteases, the proteasome harbors six individual proteases within a single macromolecular complex. This unique arrangement poses formidable challenges by requiring simultaneous activation or inhibition of all six active sites. Recent work from multiple labs has uncovered key aspects of assembly-coupled autocatalytic activation as well as the mechanism of proteasome inhibition by the endogenous inhibitor PI31 (proteasome inhibitor 31 kDa). These elegant mechanisms highlight and expand the remarkable complexity and beauty of protease biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.